KYMRKymera Therapeutics, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 17883
Ticker: KYMR
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2020-08-21
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: KYMR

Detail

Enriched 2026-08-14 20:47

Market cap: $9,481,664,970.54
Shares outstanding (class): 83,150,618
Shares outstanding (weighted): 83,150,618
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 273
Location: WATERTOWN, MA
Homepage: https://www.kymeratx.com
Description: Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Market cap and share counts drift.

Funds holding this security

183 funds · 187 positions · $1.95B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$173.42M	0.01%	2,082,159 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$162.16M	1.27%	1,946,980 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$125.43M	0.08%	1,505,906 NS	FIGI
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$123.78M	0.15%	1,486,128 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$116.65M	0.16%	1,400,582 NS	FIGI
T. Rowe Price Capital Appreciation Fund T. ROWE PRICE CAPITAL APPRECIATION FUND, IN…	—	$115.72M	0.17%	1,389,400 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$86.56M	1.16%	1,039,280 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$83.49M	0.77%	1,002,367 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$70.12M	0.18%	841,854 NS	FIGI
T. Rowe Price Small-Cap Stock Fund, Inc. T. ROWE PRICE SMALL-CAP STOCK FUND, INC.	—	$65.88M	0.82%	790,951 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$57.14M	0.07%	686,061 NS	FIGI
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$52.14M	3.28%	626,000 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$47.23M	0.57%	567,076 NS	FIGI
T. Rowe Price Mid-Cap Growth Fund, Inc. T. ROWE PRICE MID-CAP GROWTH FUND, INC.	—	$43.73M	0.19%	525,000 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$43.43M	0.53%	521,385 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERKYMR
FIGI_COMPOSITEBBG00SDHC8D1
FIGI_SHARE_CLASSBBG00SDHC8F9
CIK0001815442
ISINUS5015751044
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Kymera Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies, fitting the biotechnology industry.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.